Aardvark Therapeutics Inc

AARD exhibits a medium-term bullish continuation with price consistently above the rising 9- and 20-day EMAs and the 50-day SMA, supported by shallow pullbacks and steady demand. In the short term, price is tightly tracking the EMAs with neutral RSI and no exhaustion, favoring immediate participation. The long-term trend remains bearish as price sits below the declining 200-day SMA, underscoring structural resistance ahead. A buy-on-pullback into the EMAs is appropriate while monitoring for a decisive break above the 200-day SMA for a shift in secular bias.

• ↑Unique Prader-Willi niche; ARD-101 success could unlock unmet demand
• ↑$73.9M cash runway to late 2027; R&D spend cut to $10.5M
• ↓FDA’s full clinical hold halts ARD-101 HERO/OLE trials, delaying launch